CORDIS
EU research results

CORDIS

English EN
Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders

Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders

Objective

COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism, and schizophrenia. We capitalise on comorbidity, from clinic to cells and synapses, and have access to large existing samples. We focus on rare genetic variants of strong effect in patients with clinical comorbidity.
Our aims are: (1) Understand comorbidity by comparing symptom and syndrome overlap with novel neurobiological criteria; (2) Elucidate mechanisms of comorbidity using neurobiology for the major genomic clue of synaptic dysfunction to unravel the cellular mechanisms of comorbidity; (3) Generate novel neuronal cell models by using advanced technologies to make neurons from carefully selected patients, and use genome editing to create or correct genetic variants. Multiple advanced neuroscience platforms are in place to evaluate an extensive set of molecular and cellular parameters, and to identify alterations in synaptic biology characteristic of ID, autism, and schizophrenia. These cellular models will, with Pharma partners, be up-scaled to provide “industry-standard” cellular assays for compound screening; (4) Refine diagnostic tools, use novel genomic and cellular features to improve disease classification and discriminate specific patient subtypes; and (5) Case studies in precision medicine: with Pharma partners, identify patients with a genetic change whose consequences can be reproducibly ameliorated in vitro by an approved medication. Recommend to the patient and clinician a double-blinded, N-of-one crossover case study to evaluate the clinical utility of a medication precisely indicated for that person.
COSYN is an integrated, state-of-art, bench-to-bedside programme focused on personalised therapeutics. COSYN is a crucial next step in “decoding” the genetic findings via intensive focus on the clinical and molecular comorbidities of ID, autism, and schizophrenia.

Coordinator

KAROLINSKA INSTITUTET

Address

Nobels Vag 5
17177 Stockholm

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 675 000

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUT PASTEUR

France

EU Contribution

€ 225 000

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 800 000

UNIVERSITAETSKLINIKUM BONN

Germany

EU Contribution

€ 600 000

CARDIFF UNIVERSITY

United Kingdom

EU Contribution

€ 225 000

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 225 000

STICHTING VU

Netherlands

EU Contribution

€ 1 925 000

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 75 000

SYNAPTOLOGICS BV

Netherlands

EU Contribution

€ 650 000

CEGAT GMBH

Germany

EU Contribution

€ 100 000

LIFE AND BRAIN GMBH

Germany

EU Contribution

€ 300 000

H. LUNDBECK AS

Denmark

EU Contribution

€ 75 000

F. HOFFMANN-LA ROCHE AG

Switzerland

VERENIGING SAMENWERKENDE OUDER- EN PATIENTENORGANISATIES

Netherlands

EU Contribution

€ 50 000

Project information

Grant agreement ID: 667301

Status

Ongoing project

  • Start date

    1 January 2016

  • End date

    31 December 2020

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 6 000 000

  • EU contribution

    € 5 925 000

Coordinated by:

KAROLINSKA INSTITUTET

Sweden